Press Releases Ypsomed Group

Burgdorf – The shareholders of Ypsomed Holding AG approved all proposals by the board of directors by a large majority at the regular general meeting held on 29 June 2016. For the past 2015/16 business year, a dividend of CHF 1.00 per share, exempt from withholding tax, will be paid to shareholders from reserves arising from capital contributions.

Burgdorf – To deliver innovative care solutions, that improve the lives of people with diabetes, is the focus of the collaboration between Ypsomed and Novo Nordisk: Ypsomed’s own developed insulin pump mylife YpsoPump is fully compatible with NovoRapid PumpCart by Novo Nordisk.

Press Releases Ypsomed Group

Burgdorf – What began by establishing the Décolletage AG company 100 years ago and was continued from 1994 as a company within the Disetronic/Ypsomed Group is now Ypsotec: an internationally operating and successful vendor in the fields of precision engineering and medical technology with over 160 employees in Europe. Ypsotec AG will be celebrating its long and successful company history at a number of events.

Press Releases Ypsomed Group

Burgdorf – In the business year 2015/16, the Ypsomed Group generated consolidated sales totaling CHF 336.9 million (prior year: CHF 306.6 million). Compared with the previous year, this represents an increase in sales of 9.9%. The operating results (EBIT) also increased by 55.7% compared to the previous year, from CHF 28.5 million to CHF 44.4 million and lies considerably above the expectations of CHF 41 million. As a result, the profitability at the EBIT level lies at 13.2% (prior year: 9.3%) – despite the present currency exchange situation. For the current business year 2016/17, Ypsomed expects an accelerated growth in sales of around 12% and an EBIT of approximately CHF 55 million.

Press Releases Ypsomed Group

Burgdorf – From March 2016 the Ypsomed Group will be gradually introducing the tubing free insulin patch pump mylife OmniPod for distribution via existing Group companies also in France, Finland, Denmark, Ireland and Luxembourg. In so doing Ypsomed is taking a considerable step towards expanding the growth basis of its diabetes supply business.